Previous Next

ARCHIVE

№1' 2016

THERAPY

International Medical Journal, Vol. 22., Iss. 1, 2016, P. 27−29.

THE USE OF ALPHA-LIPOIC ACID IN PATIENTS WITH CHRONIC ACALCULOUS CHOLECYSTITIS IN COMBINATION WITH CORONARY ARTERY DISEASE

Kharkiv National Medical University, Ukraine

Increase in the level of GSH and cytosolic enzymes (MPO and GT) in plasma is observed in CAC in combination with coronary artery disease as a result of oxidative stress contributing to increased permeability of plasma membranes and cytolysis of hepatocytes. The study of glutathione system in the examined patients before treatment demonstrated an increase in the concentration of GSH in plasma (0.016±0.01 mmol/g and 0.03±0.02 mg/g; p < 0.05), levels of GR (0.39±0.05 ?mol/min per mg of protein to 0.45±0.03 µmol/min per mg of protein; p < 0.05), MPO (0.98±0.03 µmol/min per mg of protein to 1.59±0.02 µmol/min per mg of protein; p < 0.05) and GT (p < 0.05). The increase in the content of GR in erythrocytes may be due to not only activation of the enzyme by oxidative stress induced by inflammation and its absorption to the precursors of erythrocytes. The GT level in erythrocytes in patients of both groups before the treatment was reduced compared to the controls (5.57 to 3.76; p < 0.01). Treatment with additional application of Espa−lipon in patients of the main group decreased the concentration of GSH in plasma (0.018 mmol/l; p < 0.05) and increased G (p < 0.01), indicating stabilization of hepatocyte membranes. In the comparison group, receiving conventional treatment, significant differences in glutathione system in erythrocytes and plasma was observed (p > 0.5). Administration of Espa−lipon in patients with chronic acalculous cholecystitis in combination with coronary artery disease contributes to decrease in activity of lipid peroxidation and increased activity of antioxidative protection system.

Key words: chronic acalculous cholecystitis, coronary artery disease, Espa−lipon.